Contactin-Associated Protein-2 (CASPR2) Antibody, IgG by CBA-IFA

Synonyms

  • CONTACTIN-ASSO PROTEIN-2 AB IGG BY CBA-IFA, SERUM
  • CONTACTIN-ASSO PROTEIN-2 AB IGG BY CBA-IFA, SER
  • LAB11048

Cerner Name

Contactin-Asso Protein-2 Ab IgG by CBA-IFA, Serum

Clinical Info

Aid in diagnosis of contactin associated protein 2 (CASPR2) antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Use to manage antibody-positive (CASPR2) individual following immunotherapy and/or plasmapheresis.

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

Blood

Specimen Volume

1 mL serum (0.2mL min)

Container

Gold Top Tube

Collection Instructions

Container/Tube:  Gold top tube
Specimen: 1 mL serum (0.2mL min)
Transport Temperature: Refrigerated

Transport Instructions

Refrigerated

Specimen Stability

Methodology

Semi-Quantitative Indirect Fluorescent Antibody

Days Performed

Wednesdays
 
TAT 2 - 9 days

Performing Laboratories

ARUP Laboratories

CPT

86255
If reflexed add 86256
 
LOINC: 82979-6

PDM

1759245

Results
Component Name Base Name Common Name External Name
CASPR2 AB IGG SCREEN BY IFA CASPR2 CASPR2 AB IGG SCREEN BY IFA CASPR2 Ab IgG Screen by IFA
CASPR2 AB IGG TITER BY IFA CASPR2 CASPR2 AB IGG TITER BY IFA CASPR2 Ab IgG Titer by IFA

Result Interpretation

Less than 1:10
 
Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy and Morvan syndrome. Tumors such as thymoma, small-cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody
 
This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions

Forms
Immunology LAB11048 build edit